Table 2 Tumor responses

From: A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma

 

Patients (N = 33)

Best overall response

   Complete response

1 (3.0)

   Partial response

12 (36.4)

   Stable disease

10 (30.3)

   Progressive diseasea

7 (21.2)

   Not evaluableb

3 (9.1)

Objective response

39.4% (22.9-57.9)

Disease control

69.7% (51.3–84.4)

Time to response, months

2.2 (2.1-4.1)

  1. Data are presented as n (%), % (95% confidence intervals), or medians (interquartile range). Responses were evaluated by investigators according to the Response Evaluation Criteria in Solid Tumors version 1.1.
  2. aThe target lesion of one patient had not been measured at post-baseline but a new lesion appeared during treatment, so the overall response was determined as progressive disease.
  3. b“Not evaluable” indicates patients who did not undergo post-baseline tumor response evaluation.
Back to article page